Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab plus radiotherapy in locally advanced head and neck squamous cell carcinoma
2008-000781-23Phase 2Terminated
- Sponsor
- Genmab
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalutumumab in head and neck squamous cell carcinoma (HNSCC) and laryngeal squamous cell carcinoma (LSCC), sponsored by Genmab. Primary endpoints: Adverse events, Acute radiation toxicities and 2 more. Started Apr 2008; status: terminated.
02
Drugs
zalutumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on 2008-000781-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000781-23.